These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33131253)

  • 1. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.
    Cuadrado MM; Szydlo RM; Watts M; Patel N; Renshaw H; Dorman J; Lowdell M; Ings S; Anthias C; Madrigal A; Mackinnon S; Kottaridis P; Carpenter B; Hough R; Morris E; Thomson K; Peggs KS; Chakraverty R
    Haematologica; 2020 Nov; 105(11):2639-2646. PubMed ID: 33131253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
    Larocca A; Piaggio G; Podestà M; Pitto A; Bruno B; Di Grazia C; Gualandi F; Occhini D; Raiola AM; Dominietto A; Bregante S; Lamparelli T; Tedone E; Oneto R; Frassoni F; Van Lint MT; Pogliani E; Bacigalupo A
    Haematologica; 2006 Jul; 91(7):935-40. PubMed ID: 16818281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Shahzad M; Siddiqui RS; Anwar I; Chaudhary SG; Ali T; Naseem M; Ahmed TF; Ahmed Z; Khurana S; Ahmed N; Balusu R; Singh AK; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transplant Cell Ther; 2021 Oct; 27(10):877.e1-877.e8. PubMed ID: 34284148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation.
    Prabahran A; Koldej R; Chee L; Wong E; Ritchie D
    Leuk Lymphoma; 2021 Jun; 62(6):1482-1489. PubMed ID: 33522344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation.
    Stasia A; Ghiso A; Galaverna F; Raiola AM; Gualandi F; Luchetti S; Pozzi S; Varaldo R; Lamparelli T; Bregante S; Van Lint MT; di Grazia C; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1440-3. PubMed ID: 24862637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
    Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.
    Kawano Y; Takaue Y; Watanabe A; Takeda O; Arai K; Itoh E; Ohno Y; Teshima T; Harada M; Watanabe T; Okamoto Y; Abe T; Kajiume T; Matsushita T; Ikeda K; Endo M; Kuroda Y; Asano S; Tanosaki R; Yamaguchi K; Law P; McMannis JD
    Blood; 1998 Nov; 92(9):3123-30. PubMed ID: 9787147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.
    Haen SP; Schumm M; Faul C; Kanz L; Bethge WA; Vogel W
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2241-51. PubMed ID: 26272482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.
    Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F
    Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fresh or Cryopreserved CD34
    Ghobadi A; Fiala MA; Ramsingh G; Gao F; Abboud CN; Stockerl-Goldstein K; Uy GL; Grossman BJ; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1072-1077. PubMed ID: 28323004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34
    Mainardi C; Ebinger M; Enkel S; Feuchtinger T; Teltschik HM; Eyrich M; Schumm M; Rabsteyn A; Schlegel P; Seitz C; Schwarze CP; Müller I; Greil J; Bader P; Schlegel PG; Martin D; Holzer U; Döring M; Handgretinger R; Lang P
    Br J Haematol; 2018 Jan; 180(1):90-99. PubMed ID: 29205259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
    Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of CD34(+) selected stem cells for the treatment of poor graft function after allogeneic stem cell transplantation].
    Fei XH; He JB; Cheng HY; Yin YM; Zhang WJ; Zhang SQ; Wang XC; Wang JB
    Zhonghua Xue Ye Xue Za Zhi; 2018 Oct; 39(10):828-832. PubMed ID: 30369204
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation.
    Xiao Y; Song J; Jiang Z; Li Y; Gao Y; Xu W; Lu Z; Wang Y; Xiao H
    Int J Med Sci; 2014; 11(6):652-7. PubMed ID: 24834012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.